Polycystic ovarian syndrome is named for a finding — multiple small cysts on the ovaries — that is neither required for diagnosis nor uniquely characteristic of the condition. The name is a historical artifact that obscures what PCOS actually is: a complex endocrine and metabolic disorder driven primarily by insulin resistance and androgen excess, with wide-ranging effects on reproductive function, metabolic health, cardiovascular risk, and psychological wellbeing.
The Three Root Drivers
Insulin resistance is present in 65–80% of women with PCOS, regardless of body weight. High circulating insulin stimulates the ovaries to overproduce androgens (testosterone and androstenedione), disrupts the normal follicular development that leads to ovulation, and drives the characteristic hormonal profile of PCOS. Treating PCOS without addressing insulin resistance is symptomatic management that fails to address the underlying pathophysiology.
Androgen excess — elevated testosterone, DHEA-S, or androstenedione — drives many of the most visible PCOS symptoms: acne (particularly cystic acne on the jaw and chin), hirsutism (male-pattern facial and body hair growth), and androgenic alopecia (thinning hair at the crown and temples). Androgen excess also impairs ovarian follicular development, preventing dominant follicle selection and ovulation — the mechanism by which PCOS causes infertility.
Chronic low-grade inflammation is present in most PCOS patients and both drives and is driven by insulin resistance and androgen excess. Inflammatory markers — CRP, IL-6, TNF-α — are measurably elevated in PCOS compared to matched controls. This chronic inflammatory state contributes to cardiovascular risk, worsens insulin resistance, and may directly stimulate ovarian androgen production.
Beyond Reproduction: The Lifelong Metabolic Risk
Women with PCOS have approximately 4–7 times the lifetime risk of developing type 2 diabetes compared to women without PCOS. This risk exists across body weight — lean women with PCOS have significantly higher diabetes risk than weight-matched controls without PCOS, because the insulin resistance in PCOS is intrinsic to the condition, not simply secondary to weight.
Cardiovascular risk is significantly elevated in PCOS: higher rates of dyslipidemia (elevated triglycerides, low HDL, small dense LDL particles), hypertension, endothelial dysfunction, and arterial stiffness. Population studies show that women with PCOS have double the cardiovascular event risk of women without PCOS across their lifetimes.
The Diagnostic Problem
PCOS is diagnosed using the Rotterdam criteria, which require at least two of three findings: irregular ovulation (irregular or absent periods), clinical or biochemical signs of androgen excess, and polycystic ovarian morphology on ultrasound. This means PCOS can be diagnosed without irregular periods (in women with subtle cycle changes), without visible cysts (which is particularly common in lean women), and without obvious clinical androgen excess.
Many women with PCOS are told their tests are "normal" because physicians test only testosterone (often total testosterone, which can be normal even when free testosterone is elevated) and don't think to test DHEA-S, androstenedione, or fasting insulin. A proper evaluation includes a full androgen panel and metabolic markers — not just a single testosterone value.
Treatment That Actually Works
The most evidence-based foundational treatments for PCOS target insulin resistance directly: dietary modification (reducing refined carbohydrates, emphasizing protein and fiber), resistance training, and where appropriate, insulin-sensitizing medications. GLP-1 receptor agonists are showing substantial promise in PCOS — improving insulin sensitivity, reducing androgen excess, restoring ovulatory function, and achieving significant improvements in metabolic markers even at modest doses.
Hormonal treatments — combined oral contraceptives, anti-androgens — address symptoms without treating root causes. They are appropriate for symptom management but should be combined with metabolic approaches for long-term disease modification.